Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression
| Autor: | Fani‑Niki Varra, Viktoria‑Konstantina Varra, Andreas C. Lazaris, Aggelis Stavropoulos, Thivi Vasilakaki, Aphrodite Nonni, Nikolaos Kavantzas, M Varras, Aikaterini Tsavari |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
p53
phosphatase and tensin homolog 0301 basic medicine Cancer Research carcinoma medicine.disease_cause 03 medical and health sciences 0302 clinical medicine expression Carcinoma medicine Tensin PTEN concomitant Oncogene biology business.industry Cancer Articles medicine.disease Molecular medicine 030104 developmental biology Oncology endometrial Tumor progression 030220 oncology & carcinogenesis immunohistochemistry Cancer research biology.protein Carcinogenesis business |
| Zdroj: | Oncology Letters |
| ISSN: | 1792-1082 1792-1074 |
| DOI: | 10.3892/ol.2019.10093 |
| Popis: | Endometrial carcinoma is a common malignancy of the female genital tract. Alterations in the expression levels of various oncogenes and tumor suppressor genes serve important roles in the carcinogenesis and biological behavior of endometrial carcinoma. The aim of the present study was to evaluate the combination and individual expression of p53 and phosphatase and tensin homolog (PTEN) protein in human endometrial carcinoma. In addition, the correlation of these proteins with clinicopathological parameters was also assessed. Retrospective immunohistochemical analysis of the expression of p53 and PTEN tumor suppressor proteins was conducted in 99 women with endometrial carcinoma. The overall rate of p53 and PTEN positivity was 89 and 77%, respectively, according to the sum of stain intensity and scores of immunopositive cells. The sum of p53 positivity correlated strongly with PTEN expression (ρ=0.256; P=0.044). The concomitant sum of p53 and PTEN expression was identified in 45% of patients with endometrial adenocarcinoma. Notably, the sum of the immunohistochemical expression of p53 was significantly correlated with patient age (P=0.037), histologic type (P=0.008), histologic grade (P=0.002) and fallopian and/or ovarian invasion (P=0.014). Furthermore, PTEN expression was associated with myometrial invasion (ρ=-0.377; P=0.002) and clinical stage (P=0.019). In addition, concomitant p53 and PTEN expression was correlated with patient age (P=0.008) and histologic differentiation (P=0.028). The findings indicated a correlation between the expression of p53 and PTEN in endometrial adenocarcinoma, which suggested an intrinsic association between expression levels of these tumor suppressor genes. The study also suggested that concomitant p53 and PTEN expression contributed in characterizing the tumor behavior of endometrial carcinoma. Taken together, the present study suggested the combined expression of p53 and PTEN in the development of high-grade endometrial carcinoma in older patients. In addition, the findings indicated activation of different molecular pathways in the tumor progression between low-grade and high-grade endometrial carcinomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|